Obseva Logo highresolution.jpg
ObsEva Announces Progress on Cost Reduction Initiatives and Stay of Moratorium Proceedings
26. Oktober 2022 17:00 ET | ObsEva SA
Transition of linzagolix program to Kissei Pharmaceutical Co., Ltd. substantially complete with approximately $16.0 million savings expected from assignment of program contracts, including $3.7...
Obseva Logo highresolution.jpg
ObsEva Announces Corporate Updates
27. Juli 2022 07:00 ET | ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange   GENEVA, Switzerland – July 27, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing novel...
Obseva Logo highresolution.jpg
ObsEva Announces Corporate Updates
27. Juli 2022 01:00 ET | ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange   GENEVA, Switzerland – July 27, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing novel...
Obseva Logo highresolution.jpg
ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
28. Juni 2022 16:01 ET | ObsEva SA
  -Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy- -Theramex to commercialize Yselty®; ObsEva to...
Obseva Logo highresolution.jpg
ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
17. Juni 2022 07:00 ET | ObsEva SA
-Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy- -Theramex to commercialize Yselty®; ObsEva to...
Obseva Logo highresolution.jpg
ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
17. Juni 2022 01:00 ET | ObsEva SA
-Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy-   -Theramex to commercialize Yselty®; ObsEva to...
Obseva Logo highresolution.jpg
ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix at Multiple Congresses
25. Mai 2022 07:00 ET | ObsEva SA
-Data featured in two oral presentations at the 8th Society of Endometriosis and Uterine Disorders Congress and a poster presentation at the International Society of Gynecological Endocrinology 20th...
Obseva Logo highresolution.jpg
ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix at Multiple Congresses
25. Mai 2022 01:00 ET | ObsEva SA
-Data featured in two oral presentations at the 8th Society of Endometriosis and Uterine Disorders Congress and a poster presentation at the International Society of Gynecological Endocrinology 20th...
Obseva Logo highresolution.jpg
ObsEva Announces First Quarter 2022 Financial Results and Provides Corporate Update
17. Mai 2022 01:00 ET | ObsEva SA
-Linzagolix for uterine fibroids: Received confirmation of positive CHMP opinion for marketing authorization application; United States NDA PDUFA date in Q3:22- -Linzagolix for endometriosis:...
Obseva Logo highresolution.jpg
ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at the 2022 ACOG Annual Clinical and Scientific Meeting
09. Mai 2022 07:00 ET | ObsEva SA
-Additional data from the PRIMROSE Phase 3 studies of linzagolix featured in four posters. Oral presentation took place on May 8, 2022 at 9:15am PT/12:15pm ET- GENEVA, Switzerland May 9, 2022 –...